Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2005/006461external-prioritypatent/WO2005123125A1/en
Application filed by Glaxosmithkline Biolog SafiledCriticalGlaxosmithkline Biolog Sa
Publication of PE20061320A1publicationCriticalpatent/PE20061320A1/en
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UNA COMBINACION DE UNA PROTEINA L1 DE HPV 31 O FRAGMENTO INMUNOGENICO DE LA MISMA, UNA PROTEINA L1 DE HPV 45 O UN FRAGMENTO INMUNOGENICO DE LA MISMA O UNA PROTEINA L1 HPV 52 O FRAGMENTO INMUNOGENICO DE LA MISMA; B) UN ADYUVANTE TAL COMO 3D-MPL, SAL DE ALUMINIO, EMULSION DE ACEITE EN AGUA O COMBINACIONES DE ESTOS. DICHA COMPOSICION ES UNA VACUNA PARA LA PROTECCION CONTRA LA INFECCION Y/O ENFERMEDAD POR EL VIRUS DEL PAPILOMA HUMANO (HPV)REFERS TO A PHARMACEUTICAL COMPOSITION THAT INCLUDES: A) A COMBINATION OF A L1 PROTEIN OF HPV 31 OR IMMUNOGENIC FRAGMENT OF THE SAME, AN L1 PROTEIN OF HPV 45 OR AN IMMUNOGENIC FRAGMENT OF THE SAME OR AN INMUNOGENIC PROTEIN OF THE SAME OR A PROTEIN L1OGENICO HPV 52 THE SAME; B) AN ADJUVANT SUCH AS 3D-MPL, ALUMINUM SALT, EMULSION OF OIL IN WATER OR COMBINATIONS OF THEM. SAID COMPOSITION IS A VACCINE FOR THE PROTECTION AGAINST INFECTION AND / OR DISEASE BY HUMAN PAPILLOMA VIRUS (HPV)
PE2006000426A2005-04-262006-04-24
VACCINE AGAINST HUMAN PAPILLOMA VIRUS (HPV)
PE20061320A1
(en)
Crystalline forms of a compound derived from 2-thiazolyl-4-quinolinyl-oxy; Sodium salt of the compound, pharmaceutical composition comprising sodium salt, useful for treating hepatitis C virus infection.
Compounds derived from imidazopyridinones, tlr7 agonist; preparation procedure; intermediate compounds; pharmaceutical composition comprising them; and use in viral, bacterial and fungal infections.
Composition comprising at least one n-acetyl-lactosamine, at least one sialylated oligosaccharide and at least one fucosylated oligosaccharide and a hydrolyzate comprising partially and / or completely hydrolyzed proteins; and its use for the prevention and / or treatment of skin conditions and skin diseases.
Immunogenic composition comprising a modified live bovine viral diarrhea type 1b virus and an acceptable veterinary carrier; vaccine that includes it; and its use to prevent, treat, manage or relieve one or more symptoms of a disease caused by pestivirus.
COMPOSITION AND EFFECTIVE VACCINE TO TREAT TO PREVENT OR IMPROVE THE INOCULATION OF THE CANINE INFLUENZA VIRUS METHOD TO GENERATE AN IMMUNOGEN OF THE EQUINE INFLUENZA VIRUS OR OF THE VIRUS INFLUENZA MODEL OF THE USE OF THE CONTACT US TO DETERMINE THE COMPACT
Immunogenic formulation that confers protection against infection or pathology caused by the respiratory syncytial virus (vrs) comprising an attenuated recombinant strain of mycobacterium; and use of the immunogenic formulation to prepare a vaccine to prevent, treat or attenuate infections of vrs.
Monoclonal antibody or a fragment thereof that binds to the m2-1 protein of the human respiratory syncytial virus (RSV); nucleotide sequences; pharmaceutical composition; method of diagnosis of infection produced by vrs; kit; and use of said antibody to prepare a medicament.
A MULTICOMPONENT OR MONOCOMPONENT VACCINE, TO BE USED AGAINST CHAGAS DISEASE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PROCEDURE FOR OBTAINING THE IMMUNOGEN OF SUCH VACCINES AND NUCLEIC ACID USED IN THIS